Skip to content
OpenCapital
Get started

Integra LifeSciences IART Current portion of borrowings under securitization facility

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept iart:SecuredLongTermDebtSecuritizationProgramCurrent.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's current portion of borrowings under securitization facility.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's current portion of borrowings under securitization facility?
Integra LifeSciences (IART) reported current portion of borrowings under securitization facility of $0 in Q1 2026.
What is the long-term trend for Integra LifeSciences's current portion of borrowings under securitization facility?
Over 3 years (2020 to 2025), Integra LifeSciences's current portion of borrowings under securitization facility has grown at a -7.9% compound annual growth rate (CAGR), from $112.5M to $87.8M.